Historic Shift: U.S. Reclassifies Marijuana to Spur Industry Growth
The U.S. Department of Justice is easing restrictions on marijuana, reclassifying it from a Schedule I to a Schedule III drug. This significant policy shift aims to facilitate research, reduce tax burdens, and boost the cannabis industry. The change does not legalize marijuana nationwide.
In a historical move, the U.S. Department of Justice announced the easing of restrictions on marijuana, positioning it as less dangerous and supportive of the burgeoning cannabis industry.
The newly adjusted classification from Schedule I to Schedule III puts marijuana alongside drugs such as ketamine and testosterone rather than heroin and LSD, signaling a pivotal shift in federal drug policy.
This change aims to enhance research possibilities, lower tax burdens, and ease funding for cannabis-related companies, benefiting firms like Canopy Growth and Tilray Brands. However, this move does not equate to nationwide legalization.
ALSO READ
-
U.S. DOJ Set to Reshape Marijuana Policy in Landmark Move
-
Historic Marijuana Reform: Legal Landscape Undergoing Major Shift
-
U.S. Justice Department's Major Marijuana Reclassification
-
Marijuana Reclassification Shakes Up Cannabis Industry
-
Trump's Major Marijuana Policy Shift: Medical Cannabis Reclassified
Google News